India Glycols Ltd Q4 FY26 Earnings Analysis

- Potable Spirits segment is growing with shift towards premiumization and introduction of new premium brands; IMFL revenue share increased to ~31%, with Amrut contributing 5-6%. - Bio-Fuels business expects continued growth driven by government policies to increase ethanol blending beyond 20% and introduction of flexi-fuel vehicles. - Chemicals segment shows strong growth in performance chemicals (up 40%) and expects to double the business this year, driven by new product development and higher-value chemicals. - Ennature Biopharma is on a growth trajectory focusing on branded nutraceuticals with expansion into US and Asia Pacific markets, backed by clinical studies. - Overall company revenue grew 8.7% y-o-y with EBITDA up 24.5%, signaling strong operating performance. - Capex of ~INR830 crore invested largely in two distilleries (Gorakhpur, Kashipur) to support future capacity growth.

- Chemicals business: Expectation of improved profitability and top-line growth driven by performance chemicals, new products, and niche markets. Cautiously optimistic with potential upside projects underway. - Potable Spirits: Steady growth with premiumization strategy; EBIT margins maintained around 22%. Growth in IMFL segment and new areas like CSD and paramilitary expected to drive continued profitability. - Bio-Fuels: Strong growth with over 40% increase in top-line and doubling of EBIT in FY26; industry expected to sustain reasonable margins due to supportive government policies and potential blending percentage increases beyond 20%. - Ennature Biopharma: Currently under margin pressure, but volume growth, customer acquisition, clinical product launches, and US market expansion expected to improve profitability going forward. - Overall: FY26 EBITDA margin improved to 15.5% (up 162 bps); PAT up 26.8%. Optimism on sustaining and improving earnings across segments with strategic initiatives and market conditions.

- INR 830 crores capital expenditure in current year, primarily invested in two grain distilleries: Gorakhpur and Kashipur (~INR 400 crores). - Additional smaller capex projects recently completed. - Plans for ongoing reduction of debt with target prepayments in FY '26-'27 totaling INR 268 crores. - Continued investments in Ennature Biopharma segment focusing on manufacturing capability expansion and customer acquisition, aiming for volume growth and profitability improvement. - Focus on premiumization and expansion in Potable Spirit segment with introduction of premium brands, supporting revenue growth. - Multiple ongoing projects in Chemicals business, including carbon smart materials, oilfield chemicals, bio-based amines, dibasic esters, and personal care ingredients, with significant upside potential. - Investment in clinical studies for nutraceutical products, targeting new markets including the US. - Expectation to maintain/improve margins and growth driven by these strategic investments and ongoing capacity enhancements.

- The company has recently prepaid around INR 804 crores of debt in the quarter, funded partly by INR 467 crores from a November 2025 equity issue and the rest from cash flow. - There is a target to further reduce debt, with INR 268 crores liabilities due in FY26-27 and plans for prepayment based on cash flow, though no fixed amount is committed yet. - Interest cost is expected to reduce from current levels (around INR 25-26 crores per quarter). - Regarding equity fundraising, no mention of upcoming equity issues beyond the November 2025 infusion was made. - The company plans to monetize its JV stake partially in FY28-29 by selling an additional 24% equity, which is expected to generate significant funds for further debt repayment. - Overall, the focus is on deleveraging, with no explicit plans announced for new fundraising through debt or equity in the near future.

The transcript does not explicitly mention details on the current or expected order book or pending orders for India Glycols Limited. However, some related points can be inferred: - The nicotine business is in focus, with efforts on acquiring value-added, long-term customers to support growth and profitability (Page 17). - Ennature Biopharma expects growth and recovery driven by branded nutraceutical launches and new certifications (Page 8). - The Chemicals business is diversifying with new products and has a strong pipeline expected to drive growth (Page 8). - The Potable Spirits segment is shifting towards premium brands, aiming to increase revenue share from IMFL (Page 19). - No specific figures or timelines for orders or order book are disclosed in the transcript. Hence, while growth initiatives and customer acquisitions are highlighted, concrete current or expected order book or pending order details are not provided.